Sol Gel Technologies Ltd M&A Call Transcript
Greetings. Welcome to the Sol-Gel Technologies asset acquisition call. (Operator Instructions) Please note this conference is being recorded. I will now turn the conference over to your host, CEO, Alon Seri-Levy, you may begin.
Alon, is your phone on mute?
Thank you. Hello, everybody, and welcome to today's investor update call. Today, we announced the recent acquisition by Sol-Gel for Phase-3-ready new chemical entity orphan drug candidate, Patidegib Gel 2%, for the prevention of basal cell carcinomas or BCCs in Gorlin syndrome patients. We require these novel candidates from the Californian company, PellePharm, for $4.7 million upfront payment up to $70 million in a regulatory and commercial milestones and a single-digit sales royalties.
Together with me, our Executive Board Chairman, Moshe Arkin; and our Chief Financial Officer, Gilad Mamlok. We are very excited to share details with you about this acquisition, which we believe will drive significant value for
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
